Publication
Phase I expansion and pharmacodynamic study of the oral MEK inhibitor RO4987655 (CH4987655) in selected patients with advanced cancer with RAS-RAF mutations.
Authors not recorded
- Source
- PubMed
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CIVIC-20260908-000001
Abstract
Abstract (excerpt)
Only the opening of the abstract is shown; abstract text may carry publisher copyright.
Data not yet available
Linked entities
Linked entities (11)
How each link was made (MeSH, dictionary, registry reference, curation…) and whether it has been validated. Candidate links are not counted in entity statistics.
Validated 11
- cancerLung Non-Small Cell Carcinomacivic_curation1.00
- cancerMalignant Colorectal Neoplasmcivic_curation1.00
- cancerMelanomacivic_curation1.00
- drugMEK Inhibitor RO4987655civic_curation1.00
- geneBRAFcivic_curation1.00
- geneKRAScivic_curation1.00
- geneNRAScivic_curation1.00
- variantBRAF V600Ecivic_curation1.00
- variantBRAF Wildtypecivic_curation1.00
- variantKRAS Mutationcivic_curation1.00
- variantNRAS Mutationcivic_curation1.00
Curated evidence
Evidence citing this paper (5)
- Source
- CIViC — Clinical Interpretation of Variants in Cancer
- Dataset
- CIViC evidence items
- Version
- civic-2026-09-08
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Evidence
- expert curation
- License
- CC0 1.0
- PMID
- 24947927
- Run
- ING-CIVIC-20260908-000001
| Therapy | Cancer | Type | Level | Direction · significance | Rating (1–5) | Status | Evidence | Source |
|---|---|---|---|---|---|---|---|---|
| KRAS Mutation2 | ||||||||
| MEK Inhibitor RO4987655 | Lung Non-Small Cell CarcinomaCURATED_BROADER | Predictive | B | Does Not Support Resistance | 3 | accepted | EID997This was a phase I expansion and pharmacodynamic study of oral MEK inhibitor RO4987655 on advanced cancer. Of 18 patients with KRAS mutant non-small cell lung cancer (NSCLC), 10 experienced clinical b… (full text at CIViC) PMID 24947927 · Zimmer et al., 2014 · Open in CIViC | civic |
| 〃 | Malignant Colorectal NeoplasmCURATED_BROADER | Predictive | B | Does Not Support Sensitivity Response | 2 | accepted | EID998Phase I expansion and pharmacodynamic study of the oral MEK inhibitor RO4987655 (CH4987655). All 25 patients with KRAS mutant colorectal cancer experienced PD. Median days on treatment was 57 (5-269).… (full text at CIViC) PMID 24947927 · Zimmer et al., 2014 · Open in CIViC | civic |
| BRAF V600E1 | ||||||||
| MEK Inhibitor RO4987655 | Melanoma | Predictive | B | Does Not Support Resistance | 2 | accepted | EID994This was a phase I expansion and pharmacodynamic study of oral MEK inhibitor RO4987655 on advanced cancer. Of 17 patients with BRAF V600E melanoma, 4 achieved partial response, 5 experienced stable di… (full text at CIViC) PMID 24947927 · Zimmer et al., 2014 · Open in CIViC | civic |
| BRAF Wildtype1 | ||||||||
| MEK Inhibitor RO4987655 | Melanoma | Predictive | B | Does Not Support Resistance | 2 | accepted | EID995Phase I expansion and pharmacodynamic study of the oral MEK inhibitor RO4987655. Among 12 patients with melanoma BRAF wild type and non-NRAS or NRAS unknown status, seven patients experienced partial … (full text at CIViC) PMID 24947927 · Zimmer et al., 2014 · Open in CIViC | civic |
| NRAS Mutation1 | ||||||||
| MEK Inhibitor RO4987655 | Melanoma | Predictive | C | Does Not Support Resistance | 2 | accepted | EID996Phase I expansion and pharmacodynamic study of the oral MEK inhibitor RO4987655 (CH4987655). Among 8 patients with NRAS mutated melanoma, 3 experienced clinical benefit: 2 stable disease and 1 partial… (full text at CIViC) PMID 24947927 · Zimmer et al., 2014 · Open in CIViC | civic |